Trial Profile
A Phase II, Randomised, Double-Blind, Placebo-Controlled Pilot Efficacy Study of ADC4022 on Markers of Pulmonary Inflammation in Subjects With Moderate to Severe COPD.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Theophylline (Primary) ; Budesonide
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Argenta; Pulmagen Therapeutics
- 06 Oct 2009 Results were presented at the 19th Annual Congress of the European Respiratory Society, 12 Sep 2009.
- 27 Feb 2009 Actual patient numbers (91) added as reported by ClinicalTrials.gov.
- 27 Feb 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.